Cerebrolysin: A Brain-Derived Peptide Preparation with Neurotrophic Properties and Clinical Evidence in Alzheimer's Disease

This is a review paper summarizing preclinical and clinical research on Cerebrolysin. The preclinical work included in vitro and in vivo studies examining neurotrophic effects on different neuronal populations and neuroprotective properties after various types of lesions, with behavioral testing of learning and memory. Clinical evidence comes from trials in Alzheimer's disease patients assessing cognitive performance and overall clinical state, with follow-up periods extending to 6 months post-treatment.

Natural neurotrophic factors have long been considered promising treatments for neurodegenerative diseases, but they've been stymied by the blood-brain barrier and side effects. Cerebrolysin represents an alternative strategy — using smaller peptide fragments that can potentially overcome these delivery challenges while retaining the beneficial biological activity. The finding that cognitive improvements persist months after treatment cessation is particularly significant, as it suggests disease-modifying rather than merely symptomatic effects.

This 1998 review captures an early but important chapter in the story of peptide-based neurotherapeutics. While large neurotrophic factors like NGF and BDNF struggled with delivery and safety, Cerebrolysin showed that smaller peptide fragments could retain neurotrophic activity with better tolerability. The concept of using enzymatically processed brain-derived peptides as a drug has continued to be studied, and Cerebrolysin remains in clinical use in some countries for stroke and traumatic brain injury, though it has not gained FDA approval in the United States.

This is a narrative review, not a systematic review or meta-analysis, so there is potential for selective reporting. The clinical trial data described lacks specific patient numbers, effect sizes, or statistical analyses in the abstract. The review is authored by researchers associated with Cerebrolysin research, raising potential conflict of interest. The paper is from 1998, and the clinical evidence described was preliminary. Cerebrolysin's exact mechanism of action and which specific peptides are responsible for its effects remain unclear.